146 related articles for article (PubMed ID: 36719427)
1. Heterogeneity of [
Pan J; Zhao J; Ni X; Zhu B; Hu X; Wang Q; Wei Y; Zhang T; Gan H; Wang B; Wu J; Song S; Liu C; Ye D; Zhu Y
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1822-1832. PubMed ID: 36719427
[TBL] [Abstract][Full Text] [Related]
2. Role of baseline
Telli TA; Ozguven S; Alan O; Filizoglu N; Ozturk MA; Sariyar N; Isik S; Arikan R; Demircan NC; Basoglu T; Cetin IA; Ones T; Ercelep O; Dane F; Yumuk PF
Ann Nucl Med; 2022 Nov; 36(11):964-975. PubMed ID: 35997890
[TBL] [Abstract][Full Text] [Related]
3. Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study.
Calderoni L; Maietti E; Farolfi A; Mei R; Louie KS; Groaning M; Fanti S
J Nucl Med; 2023 Jun; 64(6):910-917. PubMed ID: 36635087
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients.
Plouznikoff N; Artigas C; Sideris S; Martinez Chanza N; Gil T; Peltier A; Flamen P
Ann Nucl Med; 2019 Dec; 33(12):945-954. PubMed ID: 31587172
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the role of Ga-68 PSMA I&T PET/CT in response evaluation to docetaxel therapy in castration resistant prostate cancer patients.
Özülker T; Özülker F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(5):292-298. PubMed ID: 32595026
[TBL] [Abstract][Full Text] [Related]
7. Response assessment using [
Grubmüller B; Rasul S; Baltzer P; Fajkovic H; D'Andrea D; Berndl F; Maj-Hes A; Grubmüller KH; Mitterhauser M; Wadsak W; Pfaff S; Shariat SF; Hacker M; Kramer G; Hartenbach M
Prostate; 2020 Jan; 80(1):74-82. PubMed ID: 31614001
[TBL] [Abstract][Full Text] [Related]
8. Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial
Emmett L; Yin C; Crumbaker M; Hruby G; Kneebone A; Epstein R; Nguyen Q; Hickey A; Ihsheish N; O'Neill G; Horvath L; Chalasani V; Stricker P; Joshua AM
J Nucl Med; 2019 Jul; 60(7):950-954. PubMed ID: 30552200
[TBL] [Abstract][Full Text] [Related]
9. Using
Denis CS; Cousin F; Laere B; Hustinx R; Sautois BR; Withofs N
J Nucl Med; 2022 Dec; 63(12):1815-1821. PubMed ID: 35450960
[TBL] [Abstract][Full Text] [Related]
10. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
[TBL] [Abstract][Full Text] [Related]
11. Pre-treatment
Eisazadeh R; Mirshahvalad SA; Schwieghofer-Zwink G; Hehenwarter L; Rendl G; Gampenrieder S; Greil R; Pirich C; Beheshti M
Mol Imaging Biol; 2024 Apr; 26(2):360-369. PubMed ID: 38360991
[TBL] [Abstract][Full Text] [Related]
12. Response assessment using
Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186
[TBL] [Abstract][Full Text] [Related]
13. The Prognostic Value of Posttreatment
Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L
J Nucl Med; 2023 Jan; 64(1):69-74. PubMed ID: 35738906
[No Abstract] [Full Text] [Related]
14. PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors.
Shagera QA; Karfis I; Kristanto P; Spyridon S; Diamand R; Santapau A; Peltier A; Roumeguère T; Flamen P; Artigas C
J Nucl Med; 2023 Dec; 64(12):1869-1875. PubMed ID: 37770114
[TBL] [Abstract][Full Text] [Related]
15. Comparison of quantitative whole body PET parameters on [
Ayati N; McIntosh L; Buteau J; Alipour R; Pudis M; Daw N; Jackson P; Hofman MS
Cancer Imaging; 2024 May; 24(1):57. PubMed ID: 38711135
[TBL] [Abstract][Full Text] [Related]
16. The role of Ga
Erdogan M; Sengul SS; Cetin B; Avcı M; Yagci S; Ozkoç I; Barikan DE; Yildiz M
Ann Nucl Med; 2022 Jun; 36(6):562-569. PubMed ID: 35397091
[TBL] [Abstract][Full Text] [Related]
17. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [
Buteau JP; Martin AJ; Emmett L; Iravani A; Sandhu S; Joshua AM; Francis RJ; Zhang AY; Scott AM; Lee ST; Azad AA; McJannett MM; Stockler MR; Williams SG; Davis ID; Hofman MS;
Lancet Oncol; 2022 Nov; 23(11):1389-1397. PubMed ID: 36261050
[TBL] [Abstract][Full Text] [Related]
18.
de Jong AC; Segbers M; Ling SW; Graven LH; Mehra N; Hamberg P; Brabander T; de Wit R; van der Veldt AAM
J Nucl Med; 2023 Oct; 64(10):1556-1562. PubMed ID: 37536738
[TBL] [Abstract][Full Text] [Related]
19. A single-center, multi-factor, retrospective study to improve the diagnostic accuracy of primary prostate cancer using [
Lv J; Yu H; Yin H; Shi Y; Shi H
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):919-927. PubMed ID: 37940684
[TBL] [Abstract][Full Text] [Related]
20.
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]